Journal of Clinical Oncology
Articles in this Issue
Cost-effectiveness of amivantamab plus lazertinib versus osimertinib plus chemotherapy for first-line treatment of <i>EGFR</i> ‐mutated advanced non–small cell lung cancer.
8621 Background: Amivantamab plus lazertinib and osimertinib plus chemotherapy are guideline-recommended first-line treatm...
An anti-EpCAM x anti-CD3 bispecific antibody, M701, for the treatment of malignant pleural effusion due to NSCLC: A prospective randomized controlled phase II trial.
12061 Background: Malignant Pleural Effusion (MPE) is a common complication in patients with advanced NSCLC, associated wi...
Phase 1, open-label, multi-center trial of RPT1G in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic syndromes/neoplasms.
TPS6601 Background: Nicotinamide phosphoribosyltransferase (NAMPT), the rate limiting enzyme in the NAD salvage pathway, r...
Cardiovascular complications in CAR T-cell therapy: Insights from a national inpatient database.
e24031 Background: CAR T-cell therapy uses engineered T lymphocytes to target tumor antigens and induce immune-mediated tu...
Targeting cancer stem cells with a novel virus-like drug conjugate.
3084 Background: Belzupacap sarotalocan (bel-sar) is a novel virus like-drug conjugate in clinical stage development for m...
Outcomes by lobular (lob) histology status at initial diagnosis in patients (pts) in the INAVO120 phase 3 trial with <i>PIK3CA</i> -mutated (mut), hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC) treated with inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV).
1079 Background: INAVO (a highly potent and selective PI3Kα inhibitor that also promotes mut p110α degradation) + PALBO +...
Line of therapy and proton pump inhibitor use as prognostic factors in advanced soft tissue sarcoma treated with immunotherapy.
e23573 Background: With the expanding use of immune checkpoint inhibitors (ICI) in selected soft tissue sarcoma (STS) subt...
Persistence of aggressive biology: Outcomes of <sup>177</sup> Lu-PSMA-617 in <i>BRCA</i> -altered mCRPC—Systematic review and meta-analysis.
e17053 Background: BRCA1/2 alterations define an aggressive subtype of metastatic castration-resistant prostate cancer (mC...
Rethinking infection prevention after modern CLL and NHL therapy: A real-world study.
e19029 Background: Infections are a major source of morbidity in patients with hematologic malignancies, particularly thos...
Pharmacokinetics and pharmacodynamics evaluation in phase I trial of APX-343A, selective NOX inhibitor targeting CAF-mediated immunosuppression in patients with advanced solid tumors.
TPS2684 Background: Cancer-associated fibroblasts (CAFs) drive fibrotic remodeling and immune exclusion in solid tumors an...
Temporal trends and disparities in liver cancer incidence in the United States, 1999–2022: A nationwide analysis.
e16216 Background: Liver cancer remains one of the most lethal malignancies in the United States, with incidence trends th...
Impact of human immunodeficiency virus on in-hospital outcomes among patients hospitalized with multiple myeloma: A National Inpatient Sample study, 2016–2022.
7552 Background: Outcomes among hospitalized patients with multiple myeloma (MM) and concomitant human immunodeficiency vi...
Untreated advanced urothelial carcinoma (aUC) in the modern treatment era: Patterns of care from a decade-long national cohort.
4570 Background: Over the past decade, the therapeutic landscape for locally advanced/unresectable and de novo metastatic...
Real-world 177Lu-PRRT experience in a lower-middle-income country (LMIC): Treatment delivery, tumor response, safety, and rechallenge patterns.
e16325 Background: 177Lu-peptide receptor radionuclide therapy (PRRT) is an established systemic option for metastatic neu...
A boost for oncology care delivery: Improving hospital throughput with a redesign of multidisciplinary rounds.
e13555 Background: Hospital capacity constraints impact patient access, team workflows, and overall efficiency of care. Mu...
Updated clinical and translational results of olverembatinib (HQP1351) in patients with succinate dehydrogenase (SDH)–deficient tumors.
11539 Background: SDH deficiency causes succinate accumulation and metabolic defects in gastrointestinal stromal tumor (GI...
Investigating reasons patients do not join a cancer clinical trial.
11092 Background: The perennial challenge to cancer clinical trials is accrual. To date, the focus to improve accruals res...
Time from diagnosis to CAR T as a predictor of outcomes in transformed follicular lymphoma: A CIBMTR real-world analysis.
e19016 Background: CD19-directed CAR T-cell therapy is effective in relapsed/refractory transformed follicular lymphoma (t...
Capsule networks for cancer imaging applications.
e13687 Background: Computer vision models are increasingly used in clinical oncology, with several FDA-approved algorithms...
Duration to treatment interval and survival outcomes in aggressive lymphoma: A U.S. academic single-center cohort.
e19048 Background: The influence of duration-to-treatment interval (DTI) on outcomes in aggressive lymphoma remains uncert...
Real-world use and prognostic performance of a 14-gene molecular risk assay in stage IA–IIA non-small cell lung cancer.
e20031 Background: Despite early diagnosis, stage IA-IIA non-small cell lung cancer (NSCLC) carries a high risk of relapse...
Cancer burden among young adults in Brazil: Incidence, stage at diagnosis, and sociodemographic shifts.
e22564 Background: Cancer incidence among young adults (YA, 20–49 years) is rising globally. Information on risk factors a...
A multicenter non-randomized phase III study of sentinel node navigation surgery for early gastric cancer.
4076 Background: Sentinel node navigation surgery (SNNS) has the potential to minimize the extent of gastrectomy, thereby...
Evolution of the therapeutic landscape in metastatic uveal melanoma: A single-institution real-world analysis of treatment efficacy and patient survival.
e21529 Background: Fifty percent of patients with uveal melanoma (UM) develop metastatic disease (90% to the liver) which...
Intraoperative precision margin assessment in breast-conserving surgery using handheld fluorescence microscopy.
580 Background: Breast-conserving surgery (BCS) is the standard treatment for early-stage breast cancer and is increasingl...